Patent Protection in Europe of Pharmaceuticals Found to have a Further Medical Indication

Abstract

Pharmaceutical Patent AnalystVol. 1, No. 1 Hot TopicPatent protection in Europe of pharmaceuticals found to have a further medical indicationJulian CockbainJulian CockbainEuropean Patent Attorney, Dehns, Willow Court, West Way, Oxford, OX2 0JB, UK. Search for more papers by this authorEmail the corresponding author at jcockbain@dehns.comPublished Online:29 Feb 2012https://doi.org/10.4155/ppa.11.2AboutSectionsView ArticleView Full TextPDF/EPUB ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareShare onFacebookTwitterLinkedInReddit View article"Patent protection in Europe of pharmaceuticals found to have a further medical indication." , 1(1), pp. 17–18Papers of special note have been highlighted as: ▪ of interestReferences1 Convention on the Grant of European Patents (European Patent Convention), 14th Edition. Munich: European Patent Office.▪ Version of the European Patent Convention as revised in 2000 and in force from December 2007.Google Scholar2 G-5/83 Second medical indication/EISAI. Official Journal of the European Patent Office.64–66 (1985).Google Scholar3 G-2/08 Dosage regime/ABBOTT RESPIRATORY. Official Journal of the European Patent Office. 456–494 (2010).Google Scholar101 G-1/08 Tomatoes/STATE OF ISRAEL. as of 9 December 2010. http://documents.epo.org/projects/babylon/eponet.nsf/0/E72204692CFE1DC3C12577F4004BEA42/$File/G1_08_en.pdf (Accessed 13 December 2011)Google ScholarFiguresReferencesRelatedDetailsCited ByA peek inside the launch issueGino D’Oca29 February 2012 | Pharmaceutical Patent Analyst, Vol. 1, No. 1 Vol. 1, No. 1 Follow us on social media for the latest updates Metrics Downloaded 366 times History Published online 29 February 2012 Published in print March 2012 Information© Future Science LtdFinancial & competing interests disclosureThe author has no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.No writing assistance was utilized in the production of this manuscript.PDF download